The Motley Fool Previous Page

Watch a 40% Decline Disappear

Brian Orelli
October 19, 2010

The greatest thing going for Johnson & Johnson (NYSE: JNJ  ) is its diversity in product offerings.

Recall after recall led to U.S. sales of over-the-counter drugs and nutritional products plunging 40% in the third quarter. That would crush most companies. Johnson & Johnson? It just laughs it off.

The company sells other consumer products, so overall U.S. consumer sales were